Skip to main content

Table 1 Patient characteristics

From: NT-proBNP correlates with LVEF decline in HER2-positive breast cancer patients treated with trastuzumab

Characteristics Total group (N = 135) [IQR], (%) Early-stage (N = 113) [IQR], (%) Advanced-stage (N = 22) [IQR], (%)
Age (years) 54 [47–61] 53 [47–60] 61 [53–65]
BMI (kg/m2) 25.6 [23.7–29.5] 25.6 [23.6–29.4] 26.1 [23.9–30.1]
Duration of trastuzumab treatment (months) 11 [11–12] 11 [11–11] 16 [9–44]
Pretreatment with anthracycline (doxorubicin) 111 (82) 107 (95) 4 (18)
Local radiotherapy 61 (45) 53 (47) 8 (36)
Cardiac condition before treatment
• Valve insufficiency 5 (3.5) 3 (2.6) 2 (9)
• Arrhythmia 5 (3.7) 4 (3.5%) 1 (4.5)
• MI/CABG/PCI 0 0 0
LVEF (%) 62 [58–65] 62 [58–65]a 61 [57–66]b
NT-proBNP (pmol/l)c 9 [5–14] 8 [5–14] 11 [7–18]
Follow-up duration (months)d 13 [11–14] 13 [11–14] 11 [9–12]
  1. Abbreviations: BMI body mass index, MI myocardial infarction, CABG coronary artery bypass graft, PCI percutaneous coronary intervention, LVEF left ventricle ejection fraction, NT-proBNP N-terminal pro-brain natriuretic peptide, IQR interquartile range
  2. aMeasured at T0
  3. bMeasured at T1
  4. cMeasured at baseline
  5. dCalculated from start anthracycline treatment to last available LVEF or NT-proBNP measurement